A Naturalistic Open-Label Study of Mirtazapine in Autistic and Other Pervasive Developmental Disorders
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to conduct a naturalistic, open-label examination of the efficacy and tolerability of mirtazapine (a medication with both serotonergic and noradrenergic properties) in the treatment of associated symptoms of autism and other pervasive developmental disorders (PDDs). METHODS: Twenty-six subjects (5 females, 21 males; ages 3.8 to 23.5 years; mean age 10.1 +/- 4.8 years) with PDDs (20 with autistic disorder, 1 with Asperger's disorder, 1 with Rett's disorder, and 4 with PDDs not otherwise specified were treated with open-label mirtazapine (dose range, 7.5-45 mg daily; mean 30.3 +/- 12.6 mg daily). Twenty had comorbid mental retardation, and 17 were taking concomitant psychotropic medications. At endpoint, subjects' primary caregivers were interviewed using the Clinical Global Impressions (CGI) scale, the Aberrant Behavior Checklist, and a side-effect checklist. RESULTS: Twenty-five of 26 subjects completed at least 4 weeks of treatment (mean 150 +/- 103 days). Nine of 26 subjects (34.6%) were judged responders ("much improved" or "very much improved" on the CGI) based on improvement in a variety of symptoms including aggression, self-injury, irritability, hyperactivity, anxiety, depression, and insomnia. Mirtazapine did not improve core symptoms of social or communication impairment. Adverse effects were minimal and included increased appetite, irritability, and transient sedation. CONCLUSIONS: Mirtazapine was well tolerated but showed only modest effectiveness for treating the associated symptoms of autistic disorder and other PDDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children
Schain, R. J., & Freedman, D. X. (1961) · The Journal of Pediatrics · doi:10.1016/s0022-3476(61)80261-8 · Cited by 579 · cited 1×
“These included elevation of whole blood 5-HT (Anderson et al. 1987; Schain and Freedman 1961), abnormal neuroendocrine responses to pharmacological probes of the 5-HT system (Hoshino et al. 1984; McBride et al. 1989), and worsening of behavioral symptoms in autistic adults after acute dietary…”
Whole blood serotonin in autistic and normal subjects
Anderson, G. M., Freedman, D. X., Cohen, D. J., Volkmar, F. R., Hoder, E. L., McPhedran, P., Minderaa, R. B., Hansen, C. R., & Young, J. G. (1987) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.1987.tb00677.x · Cited by 313
Winokur, A., Sateia, M. J., Hayes, J. B., Bayles-Dazet, W., MacDonald, M. M., & Gary, K. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00882-9 · Cited by 123
Cited by
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
“A recent open-label study of mirtazapine (mean dose, 32 mg/day) in children, adolescents, and young adults with PDDs (aged 4–24 years) found a 35% response rate in 26 patients, similar to the response rate generally observed in this population with SSRIs (Posey et al, 2001).”
ResultSelf-citationMalow, B. A., Byars, K., Johnson, K., Weiss, S., Bernal, P., Goldman, S. E., Panzer, R., Coury, D. L., & Glaze, D. G. (2012) · Pediatrics · doi:10.1542/peds.2012-0900i · Cited by 275
Pharmacological therapies for autism spectrum disorder: a review.
(2015) · PubMed Central · Cited by 150
Molecular analysis of nicotinic receptor expression in autism
Martin-Ruiz, C. M., Lee, M., Perry, R. H., Baumann, M., Court, J. A., & Perry, E. K. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.01.003 · Cited by 141
Metadata
- Authors
- Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., & McDougle, C. J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2001-09
- Volume
- 11
- Issue
- 3
- Pages
- 267-277
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2085655507
- Cited by
- 156
- References
- 4
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Naturalistic Open-Label Study of Mirtazapine in Autistic and Other Pervasive Developmental Disorders. https://app.cochat.ai/papers/10.1089/10445460152595586
- The paper
- Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., & McDougle, C. J. (2001). A Naturalistic Open-Label Study of Mirtazapine in Autistic and Other Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/10445460152595586
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.